Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | RAF1 | P04049 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.75 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157490 | 0.88 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL30630415 | 0.86 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL2390993 | 0.86 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL158303 | 0.86 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL20602392 | 0.85 | CYP3A4 (0.76) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL14145325 | 0.85 | CYP3A4 (0.76) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL6097859 | 0.85 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL25449242 | 0.84 | AR (0.73) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL2390943 | 0.84 | AR (0.97) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL28317755 | 0.84 | AR (0.97) | ARCYP3A4MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | AR 978/4885CYP3A4 708/4885MAPT 1784/4885 |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | AR 1167/4885CYP3A4 718/4885MAPT 2788/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | AR 4257/4885CYP3A4 3140/4885MAPT 2244/4885 |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | PC, GLS2, CYP27A1 | AR 2799/4885CYP3A4 718/4885MAPT 3238/4885 |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | AR 978/4885CYP3A4 708/4885MAPT 1784/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | AR 978/4885CYP3A4 708/4885MAPT 1784/4885 |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | PGF, ABCG2, PYGB | AR 4560/4885CYP3A4 111/4885MAPT 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.